← Back to Clinical Trials
Recruiting NCT07210437

NCT07210437 Longitudinal Autonomic Characterization as a Predictor for Secondary Medical Complications Post-SCI

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07210437
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Spinal Cord Injuries
Study Type INTERVENTIONAL
Enrollment 18 participants
Start Date 2026-01-31
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type INTERVENTIONAL
Interventions
Tests of sympathetic inhibitionTests of above level sympathetic activationTesting of below level sympathetic activation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 18 participants in total. It began in 2026-01-31 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research is to learn about how the body is able to balance changes in blood pressure, how that changes over time, and how these changes impact a participant's risk of developing medical problems.

Eligibility Criteria

Inclusion criteria * 18-75 years old * Spinal cord injury with neurological level of injury from C6-T12 * ASIA Impairment Scale A-D. * Either acute SCI \<3 months prior (n=10) or chronic SCI (\>1 year since injury, n=8). Exclusion criteria * Symptoms of cardiovascular (including, but not limited to: hypertension, stroke, chest pain, etc.), respiratory, peripheral neurological or autonomic disease (particularly diabetes mellitus requiring treatment); * Women who are pregnant or lactating * Taking or being administered a medication known to potentially have adverse interactions with phenylephrine * In the judgement of the principal investigator, any illness or condition that will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results.

Contact & Investigator

Central Contact

Erin Lund

✉ lund.erin@mayo.edu

📞 507-284-9298

Principal Investigator

Ryan J. Solinsky, MD

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT07210437 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Spinal Cord Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07210437 currently recruiting?

Yes, NCT07210437 is actively recruiting participants. Contact the research team at lund.erin@mayo.edu for enrollment information.

Where is the NCT07210437 trial being conducted?

This trial is being conducted at Rochester, United States.

Who is sponsoring the NCT07210437 clinical trial?

NCT07210437 is sponsored by Mayo Clinic. The principal investigator is Ryan J. Solinsky, MD at Mayo Clinic. The trial plans to enroll 18 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology